News
ICViewExpert PerspectivesMedical World NewsPathogen PlaybookVideosWebinars
Conference CoverageConference ListingAPIC Chapters
Infection Control TodaySupplements And Featured Publications
CME/CEEditorial Advisory BoardJob BoardPartnersSponsoredWhitepapers
Subscribe
Educator of the Year Official Rules2024 Educator of the Year Winner2023 Educator of the Year WinnerEducator of the Year
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • IC Trends
  • Bug of the Month
  • Featured Articles
  • Featured Columns
  • Pathogen Playbook
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
    • News
    • Subscribe
Advertisement

PrEP Data Links Anti-HIV Immune Response to Reduce Chance of Infection

June 23, 2015
Article

Research published in the Proceedings of the National Academy of Sciences found that some individuals exposed to HIV-1, but who remain uninfected, have a certain pattern of virus-specific immune responses that differentiated them from individuals who became infected. The findings build upon prior research by studying these responses in the context of a controlled clinical trial, examining a large number of subjects, and by having access to specimens saved before anyone was infected. In the future, this information could be used to assess HIV-1 infection risk or inform the design of a preventive HIV-1 vaccine.

This new research, co-authored by George Washington University (GW) researcher Douglas Nixon, MD, PhD, and colleagues at UCSF, USP in Brazil, and the Gladstone Institutes, looked at data from the Pre-exposure Prophylaxis Initiative (iPrEx) trial, the first randomized controlled trial of pre-exposure chemoprophylaxis (PrEP) in humans. Remaining specimens from the trial were used to test for naturally acquired or induced immunity to HIV-1 infection. Those who became infected typically lacked responses to two HIV-1 proteins. The finding suggests that such immune responses may play a role in blocking systemic infection after exposure to the virus.

“Research has shown that T-cell responses can be observed in virally exposed but uninfected persons,” says Nixon, chair of the Department of Microbiology, Immunology & Tropical Medicine and Walter G. Ross Professor of Basic Science Research at the GW School of Medicine and Health Sciences. “The question that has remained unanswered is whether or not these T-cell responses could be protecting people from acquiring systemic HIV infection. The rigor of the placebo-controlled iPrEx trial gave us access to the necessary data and specimens to address that question. What we found was what people have been looking for, for a long time – a correlation between future infection risk and a measureable immune response.”

Using samples from the iPrEx trial, the research team compared immune responses mounted against an array of HIV-1 antigens by peripheral blood mononuclear cell samples: 84 samples were collected prior to infection from men who became HIV-positive and 480 samples from men who remained HIV-negative throughout the trial, including those who received the drug or placebo. T-cell responses against certain HIV-1 antigens were significantly higher and more frequent among those who remained uninfected compared with those who became HIV-positive, and these responses were associated with reduced risk of infection.

“The iPrEX trial showed that pre-exposure prophylaxis (or PrEP) with emtricitabine and tenofovir disoproxil fumarate (brand name Truvada in the United States) was highly effective for HIV prevention when used,” said Dr. Robert Grant, of the Gladstone Institutes, the protocol chair of iPrEx which was sponsored by the National Institutes of Health. “Whether taking drug or placebo, the observed immune responses were still present, so the protective benefit we saw with PrEP was not due to these immune responses. The discovery that cellular immunity correlates with HIV infection risk is a distinct and very exciting one. I hope it will provide clues leading to an HIV vaccine.”

“Demonstrating HIV protection associated with vaccine or, as in this case, exposure-induced immunity is a very high bar to achieve, and appropriately so. Our findings indicate that the host immune system interfaces with the virus or its proteins more commonly than previously thought, generating naturally induced immunity in the form of T-cell responses that contribute to a persistent HIV negative status in some exposed people. Only with additional research can we truly know if these immune responses can be induced by a vaccine candidate, and whether vaccine-induced responses provide protection,” according to Dr. Esper Kallas, of USP, co-senior author of the manuscript.

“A safe, effective, and easily administered preventative HIV vaccine is still needed and remains an important public health goal. HIV’s interaction with the human immune system is complex, therefore success with a vaccine is hard to predict. Nevertheless, the possibility that T-cell immunity, in addition to antibody-derived immunity, may contribute to protection is quite promising. The more ‘shots on goal’ we can take in a given vaccine, the more likely we are to succeed at preventing infection, and perhaps most importantly eventual eradication of HIV,” says lead author Dr. Peter Kuebler.

Peter Kuebler, of the Division of Experimental Medicine at UC San Francisco, is the first author of this study. Along with Nixon and Grant, Esper Kallas, of the Division of Clinical Immunology and Allergy at the University of Sao Paulo in Sao Paulo, Brazil, are co-senior authors.

The article, “Cellular Immune Correlates Analysis of an HIV-1 Pre-exposure Prophylaxis Trial,” is available at http://www.pnas.org/content/early/2015/06/17/1501443112.abstract.

Source: George Washington University 

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content

Hot Topics With Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC

Hot Topics for IPC on July 2, 2025

Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC
July 2nd 2025
Article

This Hot Topics for IPC covers the latest on ASPR, AMR, vaccines, and a study on AMR and livestock manure from Michigan State University.


The Clean Bite

Personal Protective Equipment (PPE) for Dental Professionals: A Layered Defense

Sherrie Busby, EDDA, CDSO, CDIPC
July 1st 2025
Article

Dental infection control expert Sherrie Busby tackles PPE missteps, from chin-bra masks to cropped lab coats, reminding dental teams that proper protection is crucial, not optional.


Rebecca Battjes, MPH, CIC, FAPIC; Vidya Nankoosingh, MLT, CIC; and Peter Teska, MBA

Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25

Tori Whitacre Martonicz
June 30th 2025
Article

Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.


ACIP decides on vaccinations   (Adobe Stock 606491608 by N Lawrenson/peopleimages.com)

New ACIP Panel Backs Seasonal Flu, RSV Vaccinations, but Divisions Emerge Over Thimerosal and Infant Dosing

Richard Payerchin
June 27th 2025
Article

In its first major session under newly appointed leadership, the revamped Advisory Committee on Immunization Practices (ACIP) voted to support flu and RSV vaccinations for the 2025–2026 season, but internal debate over vaccine preservatives, access equity, and risk assessment highlighted the ideological and scientific tensions now shaping federal vaccine policy.


US Department of Health and Human Services

A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides

Richard Payerchin
June 26th 2025
Article

As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.


Jill Holdsworth, CIC, FAPIC, NREMT, CRCST, CHL; and Katie Belski, BSHCA, CRCST, CHL, CIS, CER, At HSPA25

Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski

Betsy Donahue, MA
June 26th 2025
Article

In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.

Related Content

Hot Topics With Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC

Hot Topics for IPC on July 2, 2025

Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC
July 2nd 2025
Article

This Hot Topics for IPC covers the latest on ASPR, AMR, vaccines, and a study on AMR and livestock manure from Michigan State University.


The Clean Bite

Personal Protective Equipment (PPE) for Dental Professionals: A Layered Defense

Sherrie Busby, EDDA, CDSO, CDIPC
July 1st 2025
Article

Dental infection control expert Sherrie Busby tackles PPE missteps, from chin-bra masks to cropped lab coats, reminding dental teams that proper protection is crucial, not optional.


Rebecca Battjes, MPH, CIC, FAPIC; Vidya Nankoosingh, MLT, CIC; and Peter Teska, MBA

Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25

Tori Whitacre Martonicz
June 30th 2025
Article

Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.


ACIP decides on vaccinations   (Adobe Stock 606491608 by N Lawrenson/peopleimages.com)

New ACIP Panel Backs Seasonal Flu, RSV Vaccinations, but Divisions Emerge Over Thimerosal and Infant Dosing

Richard Payerchin
June 27th 2025
Article

In its first major session under newly appointed leadership, the revamped Advisory Committee on Immunization Practices (ACIP) voted to support flu and RSV vaccinations for the 2025–2026 season, but internal debate over vaccine preservatives, access equity, and risk assessment highlighted the ideological and scientific tensions now shaping federal vaccine policy.


US Department of Health and Human Services

A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides

Richard Payerchin
June 26th 2025
Article

As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.


Jill Holdsworth, CIC, FAPIC, NREMT, CRCST, CHL; and Katie Belski, BSHCA, CRCST, CHL, CIS, CER, At HSPA25

Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski

Betsy Donahue, MA
June 26th 2025
Article

In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News